A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Recruiting
This clinical trial compares the use of a shared decision-making communication tool during a clinical encounter to standard care for improving the quality of the shared decision-making process among patients with non-small cell lung cancer. Lung cancer patients are faced with many decisions about their treatment options. Studies have found that patients are most satisfied if they perceive an effort by their physician to share decision making and are afforded sufficient time to make their decisio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
The Implementation of a Post-operative Communication App to Improve Pain Control and Opioid Use
Recruiting
Digital communication tools are becoming ubiquitous in healthcare, though their impact on patient/provider communication, healthcare utilization, and outcomes remains poorly established. M Health Fairview (MHFV) in collaboration with the Center for Learning Health System Sciences (CLHSS) Rapid Eval team will be evaluating one such communication application: OPY, which leverages the Epic-Care Companion functionality to remove barriers in communicating with the patient's care team. This project wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Pain
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Recruiting
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Pancreas Cancer, Relapse, Resistant Cancer
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Recruiting
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Gender:
ALL
Ages:
All
Trial Updated:
03/14/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Malignant Solid Neoplasm, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis, Idiopathic Cytopenia of Undetermined Significance, Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder, Ovarian Carcinoma, Myeloid Neoplasm Post Cytotoxic Therapy
Application of L-PRF in Periodontal Surgery
Recruiting
The study will compare the clinical outcomes of the two procedures, open flap debridement (OFD) compared to open flap debridement with leukocyte and platelet-rich fibrin (L-PFR) as well as differences in patient postoperative pain perception.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/14/2025
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Periodontal Diseases
Parenting in 2 Worlds Multisite Trial
Recruiting
This research study will test the effectiveness of a culturally grounded parenting intervention called Parenting in 2 Worlds (P2W). This intervention is designed for American Indian / Alaska Native (AI) parents/guardians of adolescents who reside in urban areas. This will be a multi-regional effectiveness trial across four regions: Northeast (Buffalo/Niagara), Midwest (St. Paul/Minneapolis), Mountain (Denver), and Southwest (Phoenix). There are four specific aims. First, this study will test the... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/14/2025
Locations: Phoenix Indian Center, Phoenix, Arizona +3 locations
Conditions: Parenting, Mental Health Wellness 1, Substance Use, Risky Health Behavior
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Recruiting
This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer
IHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults with Type 1 Diabetes
Recruiting
This research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to suppor... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
03/14/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +3 locations
Conditions: Type 1 Diabetes
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD
Recruiting
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Gender:
ALL
Ages:
Between 4 years and 5 years
Trial Updated:
03/14/2025
Locations: HLD200-112 Study Site, Dothan, Alabama +12 locations
Conditions: Attention Deficit Hyperactivity Disorder
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
Recruiting
The goal of this clinical trial is to compare the use of two photon fluorescence microscopy for detecting residual basal cell carcinoma during standard local excision.
Gender:
ALL
Ages:
All
Trial Updated:
03/14/2025
Locations: Rochester Dermatologic Surgery, Victor, New York
Conditions: Basal Cell Carcinoma
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
Recruiting
Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not current... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
03/14/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Endometriosis
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
Recruiting
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/14/2025
Locations: University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas +17 locations
Conditions: Charcot-Marie-Tooth Disease